Mirtor

LEAFLET INCLUDED IN THE PACKAGING: INFORMATION FOR THE USER

Warning! Keep the leaflet, information on the immediate packaging in a foreign language

Mirtor

30 mg, orally disintegrating tablets

Mirtazapine

You should carefully read the contents of the leaflet before using the medicine, as it contains important information for the patient.

• You should keep this leaflet, so that you can read it again if you need to.
• If you have any doubts, you should consult a doctor or pharmacist.
• This medicine has been prescribed specifically for you. Do not pass it on to others. The medicine may harm them, even if their symptoms are the same as yours.
• If the patient experiences any side effects, including any not listed in this leaflet, they should tell their doctor or pharmacist. See section 4.

Table of contents of the leaflet:

• 1. What is Mirtor and what is it used for
• 2. Important information before taking Mirtor
• 3. How to take Mirtor
• 4. Possible side effects
• 5. How to store Mirtor
• 6. Contents of the pack and other information

1. What is Mirtor and what is it used for

Mirtor belongs to a group of medicines known as antidepressants.
Mirtor is used to treat depression in adults.
Mirtor starts working after 1-2 weeks of use, and after 2-4 weeks, there is an improvement in well-being. If after 2-4 weeks of treatment, there is no improvement or the patient feels worse, they should consult a doctor. More information is provided in section 3, "When can you expect an improvement in your condition?"

2. Important information before taking Mirtor

When not to take Mirtor:

• if the patient is allergic to mirtazapine or any of the other ingredients of this medicine (listed in section 6). In this case, before taking Mirtor, the patient should contact their doctor as soon as possible.
• if the patient is currently taking or has taken in the recent past (within the last 2 weeks) monoamine oxidase inhibitors (MAOIs).

Warnings and precautions

Before starting to take Mirtor, the patient should discuss it with their doctor or pharmacist.

Before starting to take Mirtor, the patient should tell their doctor:

If the patient has ever had a severe skin rash or skin peeling, blisters, and (or) ulcers in the mouth after taking Mirtor.

Children and adolescents

Mirtor is not usually given to children and adolescents under 18 years of age, as its effectiveness has not been established in this age group. Additionally, patients under 18 years of age have a higher risk of side effects, such as suicidal attempts, suicidal thoughts, and hostility (mainly aggression, rebellious behavior, and anger), when taking medicines of this class. However, the doctor may prescribe Mirtor to patients of this age if they consider it to be in their best interest. If the doctor has prescribed Mirtor to a patient under 18 years of age, and any doubts arise, the patient should consult their doctor. In patients under 18 years of age taking Mirtor, the doctor should be informed if any of the above symptoms develop or worsen. The long-term effects of Mirtor on safety, including growth, maturation, and cognitive development in this age group, have not been established. Additionally, in this age group, after taking mirtazapine, significant weight gain has been observed more frequently than in adults.

Suicidal thoughts and worsening of depression

Patients with depression may sometimes have thoughts of self-harm or suicide. Such symptoms or behavior may worsen at the beginning of treatment with antidepressants, as these medicines usually start working after about 2 weeks, sometimes later. These symptoms are more likely in:

• patients who have had suicidal thoughts or attempts before;
• young adult patients. Clinical trial data show an increased risk of suicidal behavior in people under 25 years of age with mental disorders treated with antidepressants. If suicidal thoughts or attempts occur, the patient should immediately contact their doctor or go to the hospital.

It may be helpful to inform relatives or friendsabout the depression and ask them to read this leaflet. The patient may ask them to inform them if they notice that the depression or anxiety has worsened or if there are any worrying changes in behavior.
Also, when taking Mirtor, special caution should be exercised

• If the following conditions occur or have occurred:(The patient should inform their doctor about the occurrence of the following diseases before starting treatment with Mirtor, if they have not already done so.)
• epileptic seizures. If seizures occur or their frequency increases during treatment, the medicine should be discontinued and the doctor should be contacted immediately;
• liver disease, including jaundice. If jaundice occurs, the medicine should be discontinued and the doctor should be contacted immediately;
• kidney disease;
• heart diseaseor low blood pressure;
• schizophrenia. The doctor should be contacted immediately if such psychotic symptoms as paranoia worsen or increase;
• manic depression(alternating periods of elevated mood/excitement and depression). If the patient feels excessively excited, the medicine should be discontinued and the doctor should be contacted immediately;
• diabetes(it may be necessary to change the dose of insulin or other hypoglycemic medicines);
• eye diseases, such as increased intraocular pressure (glaucoma);
• urination difficultiesthat may be due to prostate enlargement;
• certain heart conditionsthat can cause changes in heart rhythm, recent myocardial infarction, heart failure, or the use of certain medicines that can cause disturbances in heart rhythm.
• If symptoms of infection occur, such as unexplained fever, sore throat, ulcers in the mouth, the medicine should be discontinued, and the doctor should be consulted immediately, and a blood morphology test should be performed. In rare cases, these symptoms may be a sign of blood cell production disorders. These symptoms are rare and usually occur after 4-6 weeks of treatment.
• Older patients are often more sensitive, especially to the side effects of antidepressants.
• Severe skin reactions have been reported, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS), during treatment with mirtazapine. If the patient notices any of the symptoms described in section 4 related to these severe skin reactions, they should immediately stop taking the medicine and consult their doctor. If the patient has ever had severe skin reactions in the past, they should not restart treatment with mirtazapine.

Mirtor and other medicines

The patient should tell their doctor or pharmacist about all medicines they are currently taking or have recently taken, as well as any medicines they plan to take.
Mirtor should not be takenin combination with:

• monoamine oxidase inhibitors (MAOIs), or within 2 weeks of stopping MAOIs. MAOIs should not be started until 2 weeks after stopping Mirtor. MAOIs include moclobemide, tranylcypromine (antidepressants), and selegiline (used to treat Parkinson's disease).

Care should be takenwhen taking Mirtor in combination with:

• other antidepressants, such as SSRIs, venlafaxine, and L-tryptophan or triptans(used to treat migraines), tramadol(a pain reliever), buprenorphine, linezolid(an antibiotic), lithium salts(used to treat certain psychiatric disorders), methylene blue(used to reduce high levels of methemoglobin in the blood), and preparations containing St. John's wort (Hypericum perforatum)(herbal preparations used to treat depression). In patients taking only Mirtor or in combination with these medicines, serotonin syndrome can occur very rarely. Some of its symptoms include sudden fever, sweating, increased heart rate, diarrhea, (uncontrolled) muscle spasms, chills, increased reflexes, anxiety, mood changes, loss of consciousness, and increased salivation. The patient should immediately contact their doctor if several of these symptoms occur at the same time.
• the antidepressant nefazodone. It may increase the level of Mirtor in the blood. The patient should inform their doctor if they are taking this medicine. It may be necessary to reduce the dose of Mirtor, and after stopping nefazodone, the dose of Mirtor may need to be increased.
• medicines used to treat anxiety and insomnia,such as benzodiazepines;
• medicines used to treat schizophrenia,such as olanzapine;
• medicines used to treat allergies,such as cetirizine;
• medicines used to treat severe pain,such as morphine. Mirtor in combination with these medicines may increase the sedation they cause.
• medicines used to treat infections,such as antibacterial medicines (erythromycin), antifungal medicines (such as ketoconazole), and medicines used to treat HIV/AIDS (such as HIV protease inhibitors), as well as medicines used to treat stomach ulcers (such as cimetidine). If these medicines are started at the same time as Mirtor, the level of Mirtor in the blood may increase. The patient should inform their doctor if they are taking these medicines. It may be necessary to reduce the dose of Mirtor, and after stopping these medicines, the dose of Mirtor may need to be increased.
• antiepileptic medicines,such as carbamazepine and phenytoin;
• medicines used to treat tuberculosis,such as rifampicin. These medicines in combination with Mirtor may decrease the level of Mirtor in the blood. The patient should inform their doctor if they are taking these medicines. It may be necessary to increase the dose of Mirtor, and after stopping these medicines, the dose of Mirtor may need to be decreased.
• anticoagulant medicines,such as warfarin. Mirtor may increase the effect of warfarin. The patient should inform their doctor if they are taking these medicines. In the case of combination treatment with Mirtor, it is recommended to monitor blood tests.
• medicines that may affect heart rhythm, such as certain antibiotics and antipsychotic medicines.

Mirtor with food and alcohol

Drinking alcohol while taking Mirtor may cause drowsiness. It is best to avoid consuming alcohol during treatment with Mirtor.
Mirtor can be taken with or without food.

Pregnancy and breastfeeding

If the patient is pregnant, breastfeeding, thinks they may be pregnant, or plans to have a child, they should consult their doctor or pharmacist before taking this medicine.
Limited experience with the use of Mirtor in pregnant women does not indicate an increased risk. However, caution should be exercised when using the medicine during pregnancy.
If Mirtor is taken during pregnancy or shortly before birth, it is recommended to monitor the newborn for possible side effects.
Similar medicines (from the SSRI group) taken by pregnant women may increase the risk of a serious condition in the child, called persistent pulmonary hypertension of the newborn (PPHN), which causes rapid breathing and blue discoloration of the skin. These symptoms usually occur in the first day of life. If this happens, the patient should immediately contact their midwife and (or) doctor.

Driving and using machines

Mirtor may reduce alertness and ability to concentrate. During treatment with Mirtor, the patient should avoid performing potentially hazardous tasks that require continuous attention, such as driving or operating machinery. If the doctor has prescribed Mirtor to a patient under 18 years of age, the patient should make sure that the medicine does not disrupt their concentration and alertness before participating in traffic (e.g., when cycling).

• under 18 years of age, the patient should ensure that the medicine does not disrupt their concentration and alertness before participating in traffic (e.g., when cycling).

Mirtor contains aspartame (E 951), a source of phenylalanine

This medicine contains aspartame (E 951), which is a source of phenylalanine. Each 30 mg orally disintegrating tablet contains 6 mg of aspartame (E 951). Aspartame (E 951) may be harmful to patients with phenylketonuria. This is a rare genetic disorder in which phenylalanine accumulates in the body due to its improper elimination.

3. How to take Mirtor

This medicine should always be taken exactly as prescribed by the doctor or pharmacist. In case of doubts, the patient should consult their doctor or pharmacist.

Dosage

The recommended initial dose is 15 or 30 mg per day.After a few days of treatment, the doctor may recommend increasing the dose to the most suitable for the patient (from 15 to 45 mg per day). Usually, the same dose of the medicine is used in patients of different ages. However, older patients or patients with kidney and liver diseases may be prescribed a different dose of Mirtor by their doctor.

When to take Mirtor

Mirtor should be taken every day at the same time, preferably in a single dose in the evening, before going to bed. However, the doctor may recommend taking two doses divided throughout the day - one in the morning and one in the evening before bedtime. The larger dose should be taken in the evening, before going to bed.
Information about taking orally disintegrating tablets:Mirtor tablets should be taken orally.
1 Do not crush the orally disintegrating tablet
To avoid crushing the orally disintegrating tablet, do not press on the blister (Figure A).

Figure A

2. Tear off the blister

Each blister contains 6 pockets with tablets, separated by a perforated line. The patient should bend the blister and tear off one pocket along the perforated line (Figure 1).

Figure 1

3. Tear off the foil

The patient should carefully tear off the covering foil, starting from the corner marked with an arrow (Figures 2 and 3).

Figure 2

Figure 3

4. Remove the orally disintegrating tablet

The patient should remove the orally disintegrating tablet with dry hands from the packaging and place it on their tongue. (Figure 4).

Figure 4

The tablet dissolves quickly and can be swallowed without drinking water.

When can you expect an improvement in your condition

The first signs of the medicine's effect can be expected after 1-2 weeks of treatment, and after 2-4 weeks, there may be an improvement in well-being.
It is essential to discuss the effects of Mirtor with the doctor during the first few weeks of treatment:

• After 2 to 4 weeks from the start of Mirtor treatment, the patient should discuss the treatment effects with their doctor. If there is no adequate clinical response, the doctor may increase the dose. After another 2 to 4 weeks, the patient should again discuss the treatment effects with their doctor. Treatment should be continued until the symptoms have completely disappeared, which usually takes 4 to 6 months.

Taking a higher dose of Mirtor than recommended

If the patient or anyone else has taken a higher dose of Mirtor than recommended, they should immediately consult their doctor.
Expected signs of Mirtor overdose (without other medicines and without alcohol) include drowsiness,
disorientation, and rapid heart rate.Overdose symptoms may include changes in heart rhythm (rapid heart rate, irregular heart rhythm) and (or) fainting. These may be symptoms of life-threatening ventricular arrhythmias, known as "torsades de pointes".

Missing a dose of Mirtor

If the patient forgets to take a dose that is supposed to be taken once a day

• they should not take a double dose to make up for the missed tablet. They should take the next dose at the usual time.

If the medicine is supposed to be taken twice a day

• if the patient forgets to take the morning dose, they should take it together with the evening dose;
• if the patient forgets to take the evening dose, they should not take it together with the morning dose; they should skip it and continue treatment, taking the usual morning and evening doses;

Stopping treatment with Mirtor

The patient should only stop taking Mirtor under the strict guidance of their doctor.
The patient should not stop taking the medicine too early, as it may cause the disease to recur.
If there is an improvement, the patient should discuss it with their doctor. The doctor will inform them when they can stop treatment.
Suddenly stopping treatment with Mirtor, even if the symptoms of depression have disappeared, may cause nausea, dizziness, agitation, or anxiety and headache. These symptoms will not occur during gradual withdrawal of the medicine. The doctor will inform the patient how to gradually reduce the doses of the medicine.
If the patient has any further doubts about the use of this medicine, they should consult their doctor or pharmacist.

4. Possible side effects

Like all medicines, Mirtor can cause side effects, although not everybody gets them.

In case of the following serious side effects, the patient should stop taking Mirtor and immediately consult their doctor.

Uncommon(may affect up to 1 in 100 people):

• increased mood and increased mental activity (mania)

Rare(may affect up to 1 in 1,000 people):

• yellowing of the whites of the eyes and skin, which may indicate liver problems (jaundice)

Frequency not known(frequency cannot be estimated from the available data):

• signs of infection, such as sudden and unexplained high fever, sore throat, and ulcers in the mouth (agranulocytosis). In rare cases, mirtazapine may cause blood cell production disorders. In some people, it may cause a temporary decrease in the number of white blood cells (granulocytopenia). In rare cases, mirtazapine may cause a decrease in the number of white blood cells, red blood cells, and platelets (aplastic anemia), a decrease in platelets (thrombocytopenia), or an increase in white blood cells (eosinophilia)
• seizures (convulsions)
• a combination of symptoms such as unexplained fever, sweating, increased heart rate, diarrhea, (uncontrolled) muscle spasms, chills, increased reflexes, anxiety, mood changes, loss of consciousness, and increased salivation. In very rare cases, these symptoms may indicate the development of serotonin syndrome • suicidal thoughts or attempts
• severe skin reactions:
• red spots resembling a target or round spots, often with central blisters on the torso, skin peeling, ulcers in the mouth, throat, nose, genitals, and eyes. The occurrence of such severe skin rashes is often preceded by fever and flu-like symptoms (Stevens-Johnson syndrome, toxic epidermal necrolysis).

Other possible side effects include:

Very common(may affect more than 1 in 10 people):

• increased appetite and weight gain
• calmness or drowsiness
• headache
• dry mouth

Common(may affect up to 1 in 10 people):

• lethargy
• dizziness
• seizures or tremors
• nausea
• diarrhea
• vomiting
• constipation
• skin rash or hives
• joint pain, muscle pain
• back pain
• dizziness or fainting when changing position quickly (orthostatic hypotension)
• swelling (usually of the ankles or feet) due to fluid accumulation (edema)
• fatigue
• vivid dreams
• disorientation
• feeling anxious
• sleep disturbances
• memory problems, which usually resolve after stopping treatment

Uncommon(may affect up to 1 in 100 people):

• abnormal skin sensations, such as burning, tingling, or numbness (paresthesia)
• restless legs syndrome
• fainting
• numbness in the mouth (oral hypoesthesia)
• low blood pressure
• nightmares
• agitation
• hallucinations
• urge to move

Rare(may affect up to 1 in 1,000 people):

• muscle twitching or spasms (clonic muscle spasms)
• aggressive behavior
• abdominal pain and nausea, which may indicate pancreatitis

Frequency not known(frequency cannot be estimated from the available data):

• abnormal sensations in the mouth (oral paresthesia)
• swelling of the mouth
• generalized swelling
• localized swelling
• low sodium levels in the blood
• improper secretion of antidiuretic hormone
• severe skin reactions (blistering skin rash, erythema multiforme)
• sleepwalking (somnambulism)
• speech disorders
• increased creatine kinase levels in the blood
• urination difficulties (urinary retention)
• muscle pain, stiffness, and (or) weakness
• darkening or discoloration of urine (rhabdomyolysis)
• increased prolactin levels in the blood (hyperprolactinemia, including symptoms of breast enlargement and (or) milk secretion from the nipples)
• prolonged or painful erection

Additional side effects in children and adolescents

The following side effects were commonly observed in clinical trials with children under 18 years of age: significant weight gain, hives, and increased triglyceride levels in the blood.

Reporting side effects

If the patient experiences any side effects, including any not listed in this leaflet, they should tell their doctor or pharmacist. Side effects can be reported directly to the Department of Drug Safety Monitoring of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, Tel.: +48 22 49 21 301, Fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl. By reporting side effects, more information can be collected on the safety of the medicine.

5. How to store Mirtor

The medicine should be stored out of sight and reach of children.
The patient should not use this medicine after the expiry date stated on the carton. The expiry date refers to the last day of the month.
There are no special precautions for storage.
The patient should not use this medicine if they notice any discoloration or other signs of deterioration.
Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.

6. Contents of the pack and other information

What Mirtor contains

• The active substance of the medicine is mirtazapine. Each orally disintegrating tablet contains 30 mg of mirtazapine.
• Other ingredients of the medicine are crospovidone, mannitol, microcrystalline cellulose, aspartame (E 951), strawberry-guarana flavor, peppermint flavor, anhydrous colloidal silica, magnesium stearate.

What Mirtor looks like and contents of the pack

30 mg orally disintegrating tablet: white, round, marked with "37" on one side and "A" on the other side.
For more detailed information, the patient should contact the marketing authorization holder or the parallel importer.

Marketing authorization holder in the Czech Republic, the country of export:

Orion Corporation
Orionintie 1
FI-02200 Espoo
Finland

Manufacturer:

Orion Corporation Orion Pharma
Orionintie 1
FI-02200 Espoo
Finland

Parallel importer:

Medezin Sp. z o.o.
ul. Zbąszyńska 3
91-342 Łódź

Repackaged by:

Medezin Sp. z o.o.
ul. Zbąszyńska 3
91-342 Łódź
Marketing authorization number in the Czech Republic, the country of export: 30/415/06-C
Parallel import authorization number: 309/24

Date of leaflet approval: 30.07.2024

[Information about the trademark]